According to Ipsen's statement, Henri Beaufour was an active member of the board and a representative of the founding family. Alongside his sister Anne, he contributed to the support of the company's strategic direction and the maintenance of family values. Henri Beaufour, also an artist, was recognized for his generosity and humanity. Beech Tree and Highrock, the majority shareholders, affirm their intention to continue working together for the group's interest.
Tributes from Ipsen's Leadership
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Marc de Garidel, Chairman of Ipsen, expressed his sorrow at the loss of Henri Beaufour and praised his role in the company's development. David Loew, CEO, also shared his condolences and declared the management's commitment to continue developing Ipsen in tribute to Henri Beaufour.
About Ipsen
Ipsen is a global biopharmaceutical group, specializing in the development of innovative drugs in the fields of oncology, rare diseases, and neuroscience. Present in over 40 countries, Ipsen has research hubs in France, the United States, and the United Kingdom, and its products are distributed in over 100 countries.
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1074.9M€
Guidance from the release
Ipsen a réalisé un excellent début d'année 2026.
Croissance soutenue grâce aux trois aires thérapeutiques.
Risks mentioned
pression réglementaire anticipée sur de nouveaux médicaments
concurrence accrue sur Somatuline à cause des génériques
Opportunities identified
croissance des ventes totales du Groupe supérieure à 13,0 %
lancement de trois nouveaux programmes en phase avancée
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
